Morphogenesis, Inc. is an independently owned biotech firm in the advanced stages of clinical development. The company specializes in creating personalized cancer vaccines and modifiers for the tumor microenvironment to combat resistance to current immunotherapies. Their goal is to enhance patient well-being through the development of innovative treatments that target the fundamental mechanisms through which tumor cells evade immune detection.